In conclusion, evaluating radiographic response from 68Ga-PSMA PET images in metastatic PCa at the lesion level is subject to significant heterogeneity among imaging biomarkers, which could have important implications for assessing therapy response at individual metastatic sites. This evidence concerns the gene FOLH1 and posterior cortical atrophy.